Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06724627 · ClinicalTrials.gov registry record · NA
Application of the Belle.AI Dermatological Image Reference System for Patient Diagnosis in an Active Clinical Setting
A NA study of Skin Condition and Dermatology/Skin - Other, sponsored by BelleTorus Corporation.
- Recruiting
- Registry status
- NA
- Development phase
- 263
- Enrollment target
- 1
- Study location
NCT06724627: Recruiting NA study of Skin Condition and Dermatology/Skin - Other, sponsored by BelleTorus Corporation.
NCT06724627 is a NA study of Skin Condition and Dermatology/Skin - Other that is actively recruiting participants, run by BelleTorus Corporation. The registered enrollment target is 263 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06724627, a NA study of Skin Condition and Dermatology/Skin - Other, is actively recruiting participants, sponsored by BelleTorus Corporation.
- RECRUITING
- Registry status
- NA
- Development phase
- 263 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this research study is to test a new, investigational tool that uses artificial intelligence (AI) to help primary care providers assess skin conditions. This tool is an AI-powered dermatology image reference app that works with a smartphone. For clarity, the AI makes no diagnoses; it provides reference images. Primary care providers then use their own medical judgement and training to make the diagnosis. The sponsor aims to compare the diagnoses made by primary care providers (such as doctors, nurse practitioners, and physician assistants) with the support of the AI tool compared to a panel of dermatologists, who are setting the gold standard. By doing so, the sponsor can determine the value of the AI tool for primary care providers and understand how it might be used alongside traditional clinical care. This AI capability complies with FDA regulatory guidelines and is not considered a medical device, similar to a Google image search, which returns similar looking images for reference purposes. For intervention, they healthcare providers use their own training and clinical judgement to make the diagnosis, and not the AI.
Primary Outcome
Comparison of Belle AI's image reference system primary probability diagnosis to the reference diagnosis established by the dermatological review committee; additional evaluation of the accuracy of the second and third highest probability diagnoses determined by the Bell Image Match Score
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Dermatology/Skin - Other
Study Locations (1)
New York
- Urban Health Plan Inc. - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2024-09-16 |
| Est. Completion | 2025-06-30 |
| Phase | NA |
What NCT06724627 shows while recruiting
NCT06724627 is an interventional study that assigns participants to a tested intervention. The registered 263 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower).
The record links to 3 conditions, with Skin Condition appearing as the primary indexed condition, and to 1 intervention - of which Dermatology/Skin - Other is the first listed.
NCT06724627 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06724627 about?
NCT06724627 is a clinical study titled "Application of the Belle.AI Dermatological Image Reference System for Patient Diagnosis in an Active Clinical Setting". The goal of this research study is to test a new, investigational tool that uses artificial intelligence (AI) to help primary care providers assess skin conditions. This tool is an AI-powered dermatology image reference app that works with a smartphone. For clarity, the AI makes no diagnoses; it pro...
What is the current status of trial NCT06724627?
This trial is currently recruiting. It is a NA study. The enrollment target is 263 participants. The study started on 2024-09-16. Estimated completion is 2025-06-30.
What conditions does trial NCT06724627 study?
This clinical trial studies the following conditions: Skin Condition, Dermatology/Skin - Other, Dermatology.
What interventions are being tested in trial NCT06724627?
The interventions under investigation include: Dermatology/Skin - Other (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06724627?
This trial is sponsored by BelleTorus Corporation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06724627 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Condition
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06724627's enrollment target sits among peer trials
263 396th of 2000 higher than 1,605 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04067336 · 263 participants · Phase 1
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
- NCT06234423 · 263 participants · Phase 1
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
- NCT04101669 · 264 participants · NA
RESET System Pivotal Trial (Rev F)
- NCT04295863 · 264 participants · Phase 1
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI